This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
NKTR is due to report second-quarter results. Investors await fresh updates on rezpeg's progress across autoimmune trials.
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.
Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Indivior (INDV) Moves 5.7% Higher: Will This Strength Last?
by Zacks Equity Research
Indivior (INDV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 54.4% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
3 Reasons Growth Investors Will Love Amneal (AMRX)
by Zacks Equity Research
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is Why Growth Investors Should Buy Amneal (AMRX) Now
by Zacks Equity Research
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock?
by Zacks Equity Research
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 40% and 2.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Key Metrics Tell Us About Amneal (AMRX) Q4 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amneal Pharmaceuticals (AMRX) Q4 Earnings Lag Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -20% and 3.15%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q4 Earnings
by Zacks Equity Research
Evaluate the expected performance of Amneal (AMRX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.